Start Over

Dural arteriovenous fistulas in cerebral venous thrombosis

Authors :: Marcel Arnold
Maryam Mansour
Martin Punter
Christophe Cognard
Blake F Giarola
Fabiola Serrano
Mayte Sánchez van Kammen
Nicole A Chiota-McCollum
Masoud Ghiasian
Carlos Garcia-Esperon
Erik Lindgren
Katarina Jood
William Allingham
Jukka Putaala
Sini Hiltunen
Susanna M. Zuurbier
Eike I. Piechowiak
Jeremy Wells
Jonathan M. Coutinho
Mirjam Rachel Heldner
Suzanne M. Silvis
Turgut Tatlisumak
Antonio Arauz
Timothy Kleinig
Alexandros Rentzos
HUS Neurocenter
Department of Neurosciences
University of Helsinki
Neurologian yksikkö
Clinicum
Source :: Lindgren, Erik; Rentzos, Alexandros; Hiltunen, Sini; Serrano, Fabiola; Heldner, Mirjam R.; Zuurbier, Susanna M; Silvis, Suzanne M; Mansour, Maryam; Allingham, William; Punter, Martin N M; Giarola, Blake F; Wells, Jeremy; Sánchez van Kammen, Mayte; Piechowiak, Eike I.; Chiota-McCollum, Nicole; Garcia-Esperon, Carlos; Cognard, Christophe; Kleinig, Timothy; Ghiasian, Masoud; Coutinho, Jonathan M; ... (2022). Dural arteriovenous fistulas in cerebral venous thrombosis: Data from the International Cerebral Venous Thrombosis Consortium. European journal of neurology, 29(3), pp. 761-770. Blackwell Science 10.1111/ene.15192
Publication Year :: 2021
Publisher :: Wiley, 2021.
Abstract: BACKGROUND AND PURPOSE To explore the prevalence, risk factors, time correlation, characteristics and clinical outcome of dural arteriovenous fistulas (dAVFs) in a cerebral venous thrombosis (CVT) population. METHODS We included patients from the International CVT Consortium registries. Diagnosis of dAVF was confirmed centrally. We assessed the prevalence and risk factors for dAVF among consecutive CVT patients and investigated its impact on clinical outcome using logistic regression analysis. We defined poor outcome as modified Rankin Scale score 3-6 at last follow-up. RESULTS dAVF was confirmed in 29/1218 (2.4%) consecutive CVT patients. The median (interquartile range [IQR]) follow-up time was 8��(5-23) months. Patients with dAVF were older (median [IQR] 53��[44-61] vs. 41��[29-53] years; p��30 days: 39% vs. 7%; p��